"The research collaboration is a true joint venture," said Juri G. Gelovani, M.D., Ph.D., chairman, Department of Experimental Imaging, M. D. Anderson Cancer Center. "Our goal is to help transition preclinical studies of newly developed compounds from the lab through clinic trials to fill in the gaps of the diagnostic imaging field and develop more effective molecular therapies."

Molecular imaging biomarkers - imaging agents that characterize biological processes and disease - enable the biological mechanisms of disease to be identified and understood. Results may help physicians determine personalized therapies for patients by pinpointing the active pathways in the disease progression.


Siemens is the world's leading producer and distributor of PET tracers. PETNET, Siemens' distribution channel for biomarkers, has the largest U.S. network of cyclotron-equipped radiopharmacies, reaching as many as 99 percent of hospitals and imaging centers in the U.S.

About Siemens Medical Solutions
Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics - such as Diagnostic Products Corporation and Bayer Diagnostics - mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting www.siemens.com/medical.

Back to HCB News

More Industry Headlines